logo
Food Texture Can Slow Eating, Curb Calorie Intake From UPFs

Food Texture Can Slow Eating, Curb Calorie Intake From UPFs

Medscape11-06-2025
Food texture influences the eating rate (ER) and energy intake from ultraprocessed foods (UPFs), a small randomized, controlled trial showed.
Over a 14-day period, participants consuming a UPF diet with textures that reduced their ER had an average energy intake reduction of 369 kcal/d compared to those following a 14-day UPF diet with textures that promoted a faster ER.
'The consistency of the effect of meal texture on eating rate and intake was striking,' Ciarán G. Forde, Wageningen University, Wageningen, the Netherlands, said in a press release. 'The cumulative difference in intake on average between the two diets was over 5000 kcals across the 14-day period. Almost all participants adjusted their eating behaviors in response to the meal textures served, without any guidance or instructions or the need to consciously restrict their intake or compromise on food enjoyment and satisfaction.'
The study was presented at NUTRITION 2025 in Orlando, Florida.
Meal Satisfaction Similar
For the crossover study, 41 participants (50% men; mean age, 27 years) were randomly assigned to two 14-day diets, each with over 90% energy coming from UPFs. One diet consisted of meals and snacks with textures thought to encourage a slower eating rate (Slow-ER) and one diet consisted of textures thought to promote a faster eating rate (Fast-ER).
Meals on each diet were matched for palatability, food energy density (kcal/g), portion size (grams), total energy served (kcals), and energy derived from Nova 4 (UPF) foods. On both diet arms, participants could eat as much or as little as they wanted (ad libitum) and were instructed to eat until they were comfortably full.
The two diets were separated by a 14-day washout period.
The daily energy intake was, on average, 369 kcal/d lower on the UPF Slow-ER diet than on the UPF Fast-ER diet. The effect on energy intake was consistent and sustained across individual participants and number of days on the diet.
Meals within both diets were rated to be equally liked and familiar, and despite consuming significantly fewer calories on the Slow-ER diet, participants did not report differences in appetite sensations or meal satisfaction. There was no change in body weight pre- to post-diets and no differences in body weight between the two diets.
'Food texture-derived ER has a significant and sustained effect on energy intake of ultraprocessed diets over a 2-week period,' the authors concluded. 'This finding highlights the importance of food texture in guiding eating rate and the central role of sensory cues in regulating meal size.'
Slowing Down Works
In expert commentary on the study, Amanda Avery, PhD, RD, associate professor in Nutrition and Dietetics, University of Nottingham, Nottingham, England, said, 'The study reinforces the importance of people sitting down and taking time to enjoy their food. Eating foods quickly and 'on the hoof' may lead to extra energy intake, which may lead to weight gain. Ideally, we should be choosing foods with more texture, such as UPFs with more texture, but also balanced with vegetables, whole fruits, whole grain cereals, beans, legumes, lean meat, fish, so we have to chew the food.'
In a separate comment, Julian Hamilton-Shield, MD, professor in Diabetes and Metabolic Endocrinology, University of Bristol, Bristol, England, said, 'This study reinforces previous epidemiological, experimental, and clinical trial data demonstrating that any maneuver to slow eating rate consistently, in this current study by meal texture, reduces an individual's total calorie intake. While it can be difficult to sustain a reduced eating speed, altering food texture [to slow] eating speed seems an attractive additional tool for population-based, weight management strategies.'
Forde did not provide information on funding or potential conflicts of interest. Avery declared consulting in Nutrition, Research and Health Policy at Slimming World. Hamilton-Shield declared conducting experimental and trial studies on slowing eating speed by a different methodology, 'finding results for calorie intake in agreement with the study being described.'
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

In Darwin's wake: Two-year global conservation voyage sparks hope
In Darwin's wake: Two-year global conservation voyage sparks hope

Yahoo

timea day ago

  • Yahoo

In Darwin's wake: Two-year global conservation voyage sparks hope

After a two-year around-the-world ocean voyage inspired by Charles Darwin, scientists and crew sailed home on a historic vessel into Rotterdam Thursday bearing a warning about climate change -- but also a message of hope. The majestic three-masted Oosterschelde, the last remaining vessel from a fleet of Dutch schooners that criss-crossed the globe in the early 20th century, arrived to a welcome befitting a voyage of more than 40,000 nautical miles (74,000 kilometres, 46,000 miles). Ceremonially escorted by more than a dozen vessels ranging from tall ships to steamships, all blaring horns, the Oosterschelde received a "water cannon salute" from fire service boats, as hundreds waved and cheered from the banks. Like Darwin in 1831, the Oosterschelde departed the British port of Plymouth in August 2023 to embark on a voyage of discovery that took in the major stops explored during the British naturalist's world-changing mission aboard the HMS Beagle. From the Falkland Islands to the southern tips of Africa, South America and Australia, the trip closely shadowed Darwin's voyage that inspired his groundbreaking theory of natural selection described in "On the Origin of Species". Aboard the Oosterschelde at various points of the voyage were some of the world's best young conservationists, 100 scientists aged 18-25, selected to study a species also observed by Darwin, himself aged 22 at the time of his trip. Giant tortoises, Chilean dolphins, and howler monkeys were just some of the weird and wonderful creatures the young "Darwin Leaders" investigated, tracking changes since their appearance in "Origin of Species" two centuries ago. With "online classrooms" onboard and slick social media output, the mission also hoped to inspire a new generation around the message: "Conservation isn't about what we've lost, it's about protecting what we still have." - 'Barely anything left' - One of the Darwin Leaders, 23-year-old Lotta Baten, spent a week on the ship and conducted a study into the impact of tourism on forests in Tenerife, Spain. She said only roughly four percent of the forest that Darwin would have seen from the Beagle is still alive today, with much torn down to support the tourism industry. "There's barely anything left, mainly the strips around the coast," the Dutch-German scientist told AFP. She said it was "quite something" to follow in the footsteps of Darwin, but noted that the botanist's legacy is divided, as a European in colonial times. "He basically explored and discovered things that maybe had already been explored and discovered by people at the places themselves. And then he claimed he discovered them," said Baten. Science co-ordinator Rolf Schreuder admitted that "it's not a rosy picture", with habitat loss and climate change all transforming the environment beyond what Darwin would have recognised. "You see the natural world degrading in many places," the 55-year-old told AFP. But Schreuder, like many on board, found the mission inspiring rather than depressing. He ran more than 100 local projects during the trip with people seeking to preserve their landscapes. "We met so many great people that are actually on the ground working on the survival of those species," he said. He found himself inspired too by the young scientists, "full of ideas, full of commitment and determination to really make a difference." - 'Do another tour' - Crew member Daan van Roosmalen was a boy of 17 when he set sail on the Oosterschelde. He returned to his native Netherlands having just turned 19. "I've just been to so many places. To the Galapagos Islands, French Polynesia. We went so far away and to then sail back up this river and see the skyline of Rotterdam again is just super special," he told AFP. He said he hoped the round-the-world voyage completed by scientists and crew his age would send a message to his generation. "I think it's very important that we keep inspiring young people to look after our world, because we are going to be the ones taking over," he said. "So to see all these young conservationists putting so much effort in Mother Earth... I think that should inspire more people to also take care of our planet." And what of Darwin, the inspiration behind the mission? "I would say he would have been enthused by his fellow young people taking care of this natural world, which he described so nicely," said Schreuder. "I think he would hop on this boat again and do another tour." ric/srg/rmb

argenx Reports Half Year 2025 Financial Results and Provides Second Quarter Business Update
argenx Reports Half Year 2025 Financial Results and Provides Second Quarter Business Update

Yahoo

time2 days ago

  • Yahoo

argenx Reports Half Year 2025 Financial Results and Provides Second Quarter Business Update

$949 million in second quarter global product net sales VYVGART SC launch in CIDP progresses with more than 2,500 patients on treatment globally ARGX-119 to advance to registrational study in CMS following positive proof of concept data; three additional topline data readouts across pipeline remain on track for second half of 2025 Management to host conference call today at 2:30 PM CET (8:30 AM ET) July 31, 2025 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced its half year 2025 results and provided a second quarter business update. 'We continue to make meaningful progress towards our Vision 2030, advancing bold innovation that has already reached more than 15,000 patients globally' said Tim Van Hauwermeiren, Chief Executive Officer of argenx. 'VYVGART is delivering strong growth across all indications, formulations and regions. We are still in the early stages of capturing the full market opportunity in MG and CIDP, with the recent launch of the VYVGART SC prefilled syringe driving demand from new patients and prescribers. In MG, we are shaping the market as the fastest growing biologic, moving earlier in the patient treatment paradigm, and working toward the broadest possible label. In CIDP, we continue to see consistent patient growth, with ample runway to reach the 12,000 patients in the U.S. who remain inadequately controlled on standard of care. This is just the beginning of the larger growth opportunity ahead. With six registrational and six proof-of-concept readouts expected by the end of 2026, we are executing on our proven innovation playbook that is delivering pipeline-in-a-product opportunities aimed at transforming care for patients with high unmet need.' Advancing Towards Vision 2030 argenx has established its strategic priorities to advance Vision 2030, aiming to treat 50,000 patients globally with its medicines, secure 10 labeled indications across all approved medicines, and advance five pipeline candidates into Phase 3 development by 2030. Expand global VYVGART opportunity and launch VYVGART SC as prefilled syringe VYVGART® (IV: efgartigimod alfa-fcab and SC: efgartigimod alfa and hyaluronidase-qvfc) is a first-and-only IgG Fc-antibody fragment that targets the neonatal Fc receptor (FcRn). It is approved in three indications, including generalized myasthenia gravis (gMG) globally, primary immune thrombocytopenia (ITP) in Japan, and chronic inflammatory demyelinating polyneuropathy (CIDP) in the U.S., Japan, China, and the EU. The VYVGART-SC prefilled syringe (PFS) is now approved for use in the U.S. and EU. Generated global product net sales (inclusive of both VYVGART and VYVGART SC) of $949 million in the second quarter of 2025 Strong underlying fundamentals across key patient and prescriber metrics with 97% operational growth in product net sales year-over-year from second quarter 2024, and 19% from the first quarter of 2025 First patient dosed in Germany following European Commission (EC) approval for VYVGART-SC (vial and PFS) for CIDP PFS decision on approval for gMG and CIDP expected in Japan and Canada by end of year Evidence generation through label-enabling studies: Topline results expected in second half of 2025 for seronegative gMG (ADAPT-SERON) and first half of 2026 for ocular MG (ADAPT OCULUS) Topline results expected in second half of 2026 to support FDA submission of VYVGART IV for primary ITP (ADVANCE-NEXT) Execute 10 registrational and 10 proof-of-concept studies across efgartigimod, empasiprubart and ARGX-119 to advance the next wave of launches argenx continues to demonstrate breadth and depth within its immunology pipeline, advancing multiple first-in-class product candidates with potential across high-need indications. Efgartigimod Development Efgartigimod is being studied across 15 severe autoimmune diseases, highlighting the broad potential of FcRn biology in neurology, rheumatology, and beyond. Registrational studies are currently ongoing in idiopathic inflammatory myopathies (IIM or myositis), thyroid eye disease (TED), and Sjögren's disease Topline results from ALKIVIA study evaluating three myositis subsets (immune-mediated necrotizing myopathy (IMNM), anti-synthetase syndrome (ASyS) and dermatomyositis (DM)) expected in second half of 2026 Topline results from two registrational UplighTED studies (TED) expected in second half of 2026 Topline results from registrational UNITY study (Sjögren's disease) expected in 2027 Proof-of-concept studies ongoing in lupus nephritis (LN), systemic sclerosis (SSc) and antibody mediated rejection (AMR); topline results expected for LN in fourth quarter of 2025, SSc in second half of 2026, and AMR in 2027 Empasiprubart Development Empasiprubart, a first-in-class, humanized, monoclonal antibody that specifically binds to C2, is currently being evaluated in four indications. These include registrational studies in multifocal motor neuropathy (MMN) and CIDP, and proof-of-concept studies in delayed graft function (DGF) and DM. Topline results from registrational EMPASSION study (MMN) evaluating empasiprubart head-to-head versus IVIg expected in second half of 2026 Registrational EMVIGORATE study ongoing in CIDP evaluating empasiprubart head-to-head versus IVIg Topline results expected for DGF in the second half of 2025 and for DM in first half of 2026 ARGX-119 Development ARGX-119, a first-in-class agonist antibody that targets muscle-specific kinase (MuSK), is being evaluated in congenital myasthenic syndromes (CMS), amyotrophic lateral sclerosis (ALS), and spinal muscular atrophy (SMA). Registrational study to start in CMS in 2026 following positive Phase 1b proof-of-concept data Phase 2a proof-of-concept study ongoing in ALS; topline results expected in first half of 2026 SMA proof-of-concept study on track to start by end of year ARGX-119 R&D webinar to be hosted on September 16, 2025 Advance four new pipeline molecules and generate sustainable value through continued investment in Immunology Innovation Program argenx continues to invest in its Immunology Innovation Program (IIP) to drive long-term sustainable pipeline growth. Through the IIP, four new pipeline candidates have been nominated, including: ARGX-213, targeting FcRn and further solidifying argenx's leadership in this biology; ARGX-121, a first-in-class molecule targeting IgA; ARGX-109, targeting IL-6, which plays an important role in inflammation, and a fourth pipeline candidate, a first-in-class sweeping antibody for which the target has not yet been disclosed. Phase 1 results from ongoing ARGX-109 study expected in second half of 2025, and from ongoing ARGX-213 and ARGX-121 studies expected in first half of 2026 Entered strategic collaboration with Unnatural Products (UNP) to expand argenx discovery capabilities into the oral peptide space. This partnership reinforces argenx's commitment to enhance the patient experience and advance its pipeline of precision therapies. SECOND QUARTER 2025 FINANCIAL RESULTS argenx SEUNAUDITED CONDENSED CONSOLIDATED INTERIM STATEMENTS OF PROFIT OR LOSS Three Months Ended Six Months Ended 30 June, 30 June, (in thousands of $ except per share data) 2025 2024 2025 2024 Product net sales $ 948,594 $ 477,635 $ 1,738,644 $ 875,918 Other operating income* 18,593 11,793 35,913 26,023 Total operating income $ 967,187 $ 489,428 $ 1,774,557 $ 901,941 Cost of sales $ (110,747) $ (52,383) $ (191,552) $ (95,561) Research and development expenses (327,697) (225,286) (636,767) (450,255) Selling, general and administrative expenses (324,902) (255,699) (601,150) (491,694) Loss from investment in a joint venture (2,780) (1,521) (5,087) (3,313) Total operating expenses $ (766,126) $ (534,889) $ (1,434,556) $ (1,040,823) Operating profit/(loss) $ 201,061 $ (45,461) $ 340,001 $ (138,882) Financial income $ 38,399 $ 38,933 $ 75,517 $ 77,828 Financial expense (1,126) (572) (2,261) (1,084) Exchange gains/(losses) 48,565 (7,903) 76,003 (27,215) Profit/(Loss) for the period before taxes $ 286,899 $ (15,003) $ 489,260 $ (89,353) Income tax (expense)/benefit $ (41,541) $ 44,069 $ (74,433) $ 56,822 Profit/(Loss) for the period $ 245,358 $ 29,066 $ 414,827 $ (32,531) Profit/(Loss) for the period attributable to: Owners of the parent $ 245,358 $ 29,066 $ 414,827 $ (32,531) Weighted average number of shares used for basic profit/(loss) per share 61,084,250 59,490,437 61,034,202 59,400,217 Basic profit/(loss) per share (in $) 4.02 0.49 6.80 (0.55) Weighted average number of shares used for diluted profit/(loss) per share 65,639,446 63,893,007 65,653,007 59,400,217 Diluted profit/(loss) per share (in $) 3.74 0.45 6.32 (0.55) *Comparative figures have been presented to be consistent with the one adopted in the current period with respect to the combination of collaboration revenue and other operating income. DETAILS OF THE FINANCIAL RESULTS Total operating income for the three and six months ended June 30, 2025, was $967 million and $1,775 million, respectively, compared to $489 million and $902 million, respectively, for the same periods in 2024, and mainly consists of: Product net sales of VYVGART and VYVGART SC for the three and six months ended June 30, 2025, were $949 million and $1,739 million, respectively, compared to $478 million and $876 million, respectively, for the same periods in 2024. Other operating income for the three and six months ended June 30, 2025, was $19 million and $36 million, respectively, compared to $12 million and $26 million, respectively, for the same periods in 2024. The other operating income for the three and six months ended June 30, 2025 and 2024, primarily relates to research and development tax incentives and payroll tax rebates. Total operating expenses for the three and six months ended June 30, 2025 were $766 million and $1,435 million, respectively, compared to $535 million and $1,041 million, respectively, for the same periods in 2024, and mainly consist of: Cost of sales for the three and six months ended June 30, 2025, was $111 million and $192 million, respectively, compared to $52 million and $96 million for the same periods in 2024, respectively. The cost of sales was related to the sale of VYVGART and VYVGART SC. Research and development expenses for the three and six months ended June 30, 2025, were $328 million and $637 million, respectively, compared to $225 million and $450 million, respectively, for the same periods in 2024. The research and development expenses mainly relate to: the clinical development and expansion of efgartigimod in 15 severe autoimmune diseases; the ramp-up of studies for the development of empasiprubart into MMN, DGF, DM and CIDP; the investments for ARGX-119 in proof-of-concept studies ongoing in ALS, CMS and SMA; and other discovery and preclinical pipeline candidates. Selling, general and administrative expenses for the three and six months ended June 30, 2025, were $325 million and $601 million, respectively, compared to $256 million and $492 million, respectively, for the same periods in 2024. The selling, general and administrative expenses mainly relate to professional and marketing fees linked to the global commercialization of VYVGART franchise, and personnel expenses. Financial income for the three and six months ended June 30, 2025, was $38 million and $76 million, respectively, compared to $39 million and $78 million, respectively, for the same periods in 2024. Exchange gains for the three and six months ended June 30, 2025, were $49 million and $76 million, respectively, compared to $8 million and $27 million, respectively, of exchange losses for the same periods in 2024. Exchange gains/losses are mainly attributable to unrealized exchange rate gains or losses on the cash, cash equivalents and current financial assets denominated in Euro. Income tax for the three and six months ended June 30, 2025 and 2024 is detailed below: Three Months Ended Six Months Ended 30 June, 30 June, (in millions of $) 2025 2024 2025 2024 Current tax (expense)/benefit $ (41) $ (9) $ (70) $ (16) Deferred tax (expense)/benefit (1) 53 (4) 72 Income tax (expense)/benefit $ (42) $ 44 $ (74) $ 57 Profit for the three- and six-month periods ended June 30, 2025, was $245 million and $415 million, respectively, compared to a profit of $29 million and a loss of $33 million, respectively, for the same periods in 2024. The basic profit per share was $4.02 for the three months ended June 30, 2025, compared to a basic profit per share of $0.49 for the same period in 2024. The basic profit per share was $6.80 for the six months ended June 30, 2025, compared to a basic loss per share of $0.55 for the same period in 2024. Cash flow from operating activities for the six months ended June 30, 2025 was $362 million compared to a cash flow used in operating activities for the same period in 2024 of $126 million. FINANCIAL GUIDANCE The financial guidance on the combined research and development and selling, general and administrative remains unchanged at approximately $2.5 billion. EXPECTED 2025 FINANCIAL CALENDAR October 30, 2025: Third Quarter 2025 Financial Results and Business Update February 26, 2025: Full-year 2025 Financial Results and Fourth Quarter 2025 Business Update CONFERENCE CALL DETAILS The half-year 2025 financial results and second quarter business update will be discussed during a conference call and webcast presentation today at 2:30 pm CET/8:30 am ET. A webcast of the live call may be accessed on the Investors section of the argenx website at A replay of the webcast will be available on the argenx website. Dial-in numbers: Please dial in 15 minutes prior to the live call. Belgium 32 800 50 201 France 33 800 943355 Netherlands 31 20 795 1090 United Kingdom 44 800 358 0970 United States 1 888 415 4250 Japan 81 3 4578 9081 Switzerland 41 43 210 1132 This press release contains inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation (Regulation 596/2014). About argenx argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit and follow us on LinkedIn, Instagram, Facebook, and YouTube. For further information, please contact: Media:Ben Petokbpetok@ Investors:Alexandra Roy aroy@ Forward-looking Statements The contents of this announcement include statements that are, or may be deemed to be, 'forward-looking statements.' These forward-looking statements can be identified by the use of forward-looking terminology, including the terms 'advance,' 'aim,' 'committed,' 'continue,' 'expand,' 'expect,' 'growth,' and 'progress' and include statements argenx makes concerning its innovation agenda and growth strategy, including (i) its Vision 2030 to reach 50,000 patients globally across 10 labeled indications and to advance fix pipeline candidates into Phase 3 development by 2030 across efgartigimod, empasiprubart and ARGX-119 to create significant opportunity to expand into new therapeutic areas and reach broader patient populations and (ii) its goal to transform care for patients with high unmet need; its confidence regarding its growth trajectory; its commitment to improving the lives of people suffering from severe autoimmune diseases; its expectation regarding the insights from proof-of-concept and registrational studies across various programs; the advancement of anticipated clinical development, data readouts and regulatory milestones and plans, including: (1) the PFS decision on approval for gMG and CIDP expected in Japan and Canada by end of 2025, (2) topline results for seronegative gMG (ADAPT-SERON) expected in second half of 2025 and for ocular and pediatric MG (ADAPT-OCULUS, JR) expected in first half of 2026, (3) topline results for ADVANCE-NEXT to support FDA submission of VYVGART IV for primary ITP expected in second half of 2026, (4) new therapeutic areas and ongoing registrational studies in three subsets of myositis, thyroid eye disease (TED), and Sjögren's disease, with topline results from (a) ALKIVIA expected in second half of 2026, (b) two registrational UplightTED studies expected in second half of 2026 and (c) registrational UNITY study expected in 2027, (5) proof-of-studies ongoing in LN, SSc and AMR, with topline results expected in fourth quarter of 2025, second half of 2026 and 2027, respectively, (6) its plans to develop empasiprubart, including (a) registrational EMPASSION study in MMN, with topline results expected in second half of 2026, (b) registrational EMVIGORATE study in CIDP, expected to start in first half of 2025 and (c) topline results for DGM and DM expected in second half of 2025 and first half of 2026, respectively, (7) its plans to develop ARGX-119, including: (a) the registrational study to start in CMS in 2026; (b) Phase 2a proof-of-concept study in ALS, with topline results expected in first half of 2026; and (c) SMA proof-of-concept study; and (8) its plans to advance four new pipeline molecules and generate sustainable value through continue investment in its IIP, through (a) ongoing studies for ARGX-213 and ARGX-121, with results expected in first half of 2026, (b) ARGX-109, with Phase 1 results expected in second half of 2025, and (c) a fourth pipeline candidate, a first-in-class sweeping antibody for which the target has not yet been disclosed; and its goal of translating immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. argenx's actual results may differ materially from those predicted by the forward-looking statements as a result of various important factors, including but not limited to, the results of argenx's clinical trials; expectations regarding the inherent uncertainties associated with the development of novel drug therapies; preclinical and clinical trial and product development activities and regulatory approval requirements; the acceptance of its products and product candidates by its patients as safe, effective and cost-effective; the impact of governmental laws and regulations, including tariffs, export controls, sanctions and other regulations on its business; its reliance on third-party suppliers, service providers and manufacturers; inflation and deflation and the corresponding fluctuations in interest rates; and regional instability and conflicts. A further list and description of these risks, uncertainties and other risks can be found in argenx's U.S. Securities and Exchange Commission (SEC) filings and reports, including in argenx's most recent annual report on Form 20-F filed with the SEC as well as subsequent filings and reports filed by argenx with the SEC. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. argenx undertakes no obligation to publicly update or revise the information in this press release, including any forward-looking statements, except as may be required by in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Spetsas Buist Files Lawsuit Alleging Inadequate Monitoring at Mental Health Facility Led to Tragic Death
Spetsas Buist Files Lawsuit Alleging Inadequate Monitoring at Mental Health Facility Led to Tragic Death

Yahoo

time2 days ago

  • Yahoo

Spetsas Buist Files Lawsuit Alleging Inadequate Monitoring at Mental Health Facility Led to Tragic Death

Personal injury law firm Spetsas Buist has filed a lawsuit on the circumstances surrounding a young woman's escape from Pasadena Villa, a facility operated by Renaissance Healthcare Group, shortly before her tragic death. ORLANDO, Fla., July 30, 2025--(BUSINESS WIRE)--Spetsas Buist Accident Injury Lawyers, a personal injury and wrongful death law firm based in Orlando, has filed a lawsuit on behalf of the family of a young woman who tragically lost her life after escaping the Pasadena Villa Psychiatric Treatment facility. The facility, now known as Lifeskills Orlando, is a residential mental health facility operated by Renaissance Healthcare Group and Odyssey Behavioral Healthcare. The young woman was living at the facility and receiving residential treatment for mental health conditions at the time of her tragic passing. According to the lawsuit, the young woman, Taylor Meador, was recognized as a suicide risk while under the care of the facility. In fact, this is why she entered the facility in the first place. In an effort to protect her safety, she was to be placed under routine observation where behavioral health technicians were supposed to check on her regularly and document the check, including her whereabouts at the time, what she was doing, and when the technician performed the check. However, the lawsuit alleges that the facility failed to perform scheduled observations, which resulted in Taylor escaping from the facility without intervention. The lawsuit alleges that on October 22, 2022, Taylor was left unmonitored for a prolonged period and somehow gained unauthorized and unsupervised access to her cell phone. She then escaped the facility without intervention and used her cell phone to arrange for a rideshare service to pick her up. She arranged to be transported to a parking garage in Orlando, where she ultimately committed suicide. The lawsuit brought forth by Spetsas Buist Accident Injury Lawyers outlines claims for damages including medical and funeral expenses, loss of income and net accumulations, and the ongoing mental pain and suffering endured by her surviving family members, namely Taylor's parents. "This is a heartbreaking case involving a young woman who was in the care of a facility that her family trusted to take care of her," said attorney Nicholas Spetsas. "We are committed to seeking accountability and helping her family find answers and get justice during an unimaginable time." The case highlights broader concerns regarding practices at residential mental health facilities trusted with the most vulnerable people in our society. "Families across the United States are trusting these mental health facilities with their children, and far too often the facility lets them down," said attorney Charles Buist. "As we continue to see private equity get involved in these industries and small companies getting devoured by giant corporate entities, we need to make sure that these entities and investors understand that they have a responsibility to the families, not just to their shareholders. We want to make sure that Taylor did not die in vain. We want her death to serve as a warning to any entities that consider cutting corners to increase profits." About Spetsas Buist Spetsas Buist Accident Injury Lawyers is an Orlando-based personal injury and wrongful death law firm dedicated to fighting for justice with integrity and compassion. The firm handles complex cases involving wrongful death, negligent security, trucking accidents, and more. At Spetsas Buist, clients are given direct access to a lawyer from start to finish and only pay if they win. They combine an aggressive courtroom approach with compassionate, client-focused support to ensure every voice is heard and relentlessly represented. For more information on the firm, visit their website at For interviews with Spetsas Buist representatives or the family involved in this case, please contact Zabrina Zulaica at zabrina@ View source version on Contacts Zabrina Zulaicazabrina@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store